Skip to main content

UPDATE 1-U.S. FDA approves Lundbeck's migraine prevention therapy

The U.S. Food and Drug Administration approved Lundbeck A/S' migraine prevention therapy, which the Danish drugmaker acquired through its near $2 billion deal for Alder BioPharmaceuticals in 2019, the company said on Friday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.